2010
Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines
Hernandez-Ilizaliturri F, Mavis C, Maraj I, Chisti M, Gibbs J, Czuczman M. Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines. Blood 2010, 116: 3936. DOI: 10.1182/blood.v116.21.3936.3936.Peer-Reviewed Original ResearchCell linesBcl-xLBcl-2 family proteinsBcl-2 family membersLymphoma cell linesProteasome inhibitorsRegulation of BakAnti-tumor activityLymphoma cellsB-cell lymphomaCellular processesFamily proteinsWestern blotGene transcriptionPan-caspaseHistone deacetylase inhibitorsSingle agentTarget proteinsCaspase inhibitionMolecular eventsAlamar Blue reductionMcl-1Mitochondrial potentialATP synthesisHodgkin's lymphoma cell lines
2008
The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib. Blood 2008, 112: 4984. DOI: 10.1182/blood.v112.11.4984.4984.Peer-Reviewed Original ResearchPatient-derived tumour cellsB-cell lymphomaTarget proteinsAnti-tumor activitySequence of administrationNon-histone proteinsChemotherapy agentsCell linesTumor cellsMonoclonal antibodiesCellular processesTranscription factorsEffects of LBH589Gene transcriptionLymphoma cellsAlamar Blue reductionDeacetylasesMitochondrial potentialCell deathRituximab-resistant cell linesSchedule of administrationSignificant anti-tumor activityDAC activityPatient-derived tumor cellsNegative selection